Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy

Verónica López\textsuperscript{a,b}, Carolina Polo\textsuperscript{a,b}, Ruben Schuldt\textsuperscript{a,b}, Teresa Vázquez\textsuperscript{a,b}, Elena Gutiérrez-Vilchez\textsuperscript{a,b}, Candela Molí\textsuperscript{a,b}, and Domingo Hernández\textsuperscript{a,b}

\textsuperscript{a}Nephrology Department, Hospital Regional Universitario de Málaga, Malaga, Spain; and \textsuperscript{b}University of Malaga, IBIMA (Malaga Institute of Biomedical Research), Malaga, Spain.

ABSTRACT
Background. Messenger RNA vaccination against COVID-19 has been shown to produce an immune response with sufficient efficacy to prevent natural infection in immunocompetent recipients. However, the response in kidney transplant recipients is low. We aimed to evaluate the specific humoral response to SARS-CoV-2 after vaccination in a population of kidney transplant recipients and assess the main factors associated with a lack of response.

Methods. We undertook a prospective study of 105 kidney transplant recipients and 11 recipients of a combined kidney-pancreas transplant. We analyzed immunoglobulin G and immunoglobulin M antibodies after the patients received their second and third doses of the messenger RNA 1273 (Moderna) or BNT162b1 (BionTECH-Pfizer) vaccinations between February and November 2021.

Results. Mean (SD) age of the 116 patients was 50 (16) years, and 65% were men. They had their transplants for 40 months (IQR, 15-123 months), with 14% undergoing retransplant and 11% sensitized. The maintenance immunosuppression regimen was steroids + tacrolimus + mycophenolate (MMF) in 68% of the patients and any combination with mammalian target of rapamycin inhibitor (mTORi) in 28%. A humoral response developed in 40% of the patients 6 weeks (IQR, 4-10 weeks) after receiving the second dose of the vaccine. Of the 67 patients with no response to the second dose, 51 had an analysis of the humoral response after the third dose, which was positive in 16 (31%). A total of 80% received the Moderna vaccine and 20% the BionTECH-Pfizer. No patient experienced major adverse effects after the vaccination.

Factors associated with a lack of humoral response to the vaccine were recipient age (odds ratio [OR], 1.02; 95% CI, 1.001-1.05; \( P = .04 \)), diabetes (OR, 2.8; 95% CI, 1.2-6.9; \( P = .02 \)), and treatment with MMF (OR, 2.6; 95% CI, 1.08-6.8; \( P = .03 \)). Treatment with mTORi was associated with a better response to vaccination (OR, 0.3; 95% CI, 0.1-0.9; \( P = .04 \)).

Conclusions. The humoral response to the COVID-19 vaccine in kidney transplant recipients is poor. Factors related with this lack of immunity are recipient age and diabetes, plus MMF therapy, whereas mTORi therapy was associated with a better response to vaccination.
immunosuppressive drugs, in addition to other specific transplant-associated risk factors [3].

MATERIALS AND METHODS

This prospective, observational study included 105 recipients of a KT and 11 recipients of a combined kidney-pancreas transplant. Analyses were made in all patients of immunoglobulin G and immunoglobulin M antibodies after receiving their second and third doses of a messenger RNA vaccination (Moderna 1273 or BionTECH-Pfizer BNT162b1) between February and November 2021.

The aim was to evaluate the specific humoral response against SARS-CoV-2 after vaccination in this population and determine the main factors associated with a lack of response.

Clinical and epidemiologic data were obtained from electronic clinical records. The main aspects considered were the clinical characteristics of the patients, the time from transplant to vaccination, and the type of immunosuppression, among others. The humoral serologic response was assessed between weeks 4 and 10 after the second and third doses of the vaccination. Major adverse effects were considered to be severe allergic reaction due to the vaccination.

Statistical Analysis

The results were analyzed using SPSS version 15 for Windows (IBM, Armonk, NY). The descriptive results for continuous variables were expressed as mean (SD) unless they did not follow a normal distribution normal, in which case they were expressed as median and IQR. Qualitative variables were expressed as a percentage, number of cases of the total, and the 95% CI. Comparisons between groups were analyzed with the Student t test to compare 2 continuous variables and the non-parametric Mann-Whitney test when it was not considered suitable to use the normal distribution. The χ² test was used to compare qualitative variables, with Fisher exact test when necessary. In addition, we also undertook a multivariate logistic regression analysis to determine the risk factors associated with a lack of response to vaccination. A value of P < .05 was considered statistically significant for all analyses.

RESULTS

The mean (SD) age of the 116 patients was 50 (16) years, and 65% were men. The median time since transplant was 40 months (IQR, 15-123 months), with 14% being retransplants and 11% hypersensitized. The maintenance immunosuppression regimen received was steroids, tacrolimus, and mycophenolate mofetil (MMF) in 68% of the cases and any combination with mammalian target of rapamycin inhibitor (mTORi) in 28%. A humoral response developed in 40% of the patients 6 weeks (IQR, 4-10) weeks after receiving the second vaccine dose. Of the 67 patients who failed to respond to the second dose, 51 were evaluated after the third dose, with 16 (31%) showing a positive humoral response. A total of 80% received the Moderna vaccine and 20% the BionTECH-Pfizer vaccine.

The factors associated with a lack of humoral response to the vaccine were recipient age (odds ratio [OR], 1.02; 95% CI, 1.001-1.05; P = .04), the presence of diabetes mellitus (OR, 2.8; 95% CI, 1.2-6.9; P = .02), and treatment with MMF (OR, 2.6; 95% CI, 1.08-6.8; P = .03). Treatment with mTORi was associated with a better response to vaccination (OR, 0.3; 95% CI, 0.1-0.9; P = .04) (Tables 1 and 2). The response to the vaccination was 75% in the patients receiving mTORi vs 45% in the patients receiving MMF (P = .004) (Table 3). No patient presented major adverse effects after vaccination.

Table 1. Clinical and Laboratory Characteristics of the Patients Who Responded Compared With Those Who Failed to Respond

| Characteristic               | Responder (n = 62) | Nonresponder (n = 54) | P Value |
|------------------------------|-------------------|-----------------------|---------|
| Age, mean (SD), y            | 46 (17)           | 53 (15)               | .03     |
| Sex, % male                  | 38                | 34                    | .7      |
| Time after transplant, mean (SD), mo | 80 (92)   | 58 (78)               | .1      |
| Creatinine, mean (SD), mg/dL | 1.6 (0.8)        | 2.2 (1.1)             | .005    |
| Hypertension, %              | 88                | 89                    | .9      |
| Diabetes mellitus, %         | 26                | 66                    | <.001   |
| Ischemic heart disease, %    | 14                | 23                    | .2      |
| Retransplant, %              | 13                | 15                    | .7      |
| Hypersensitized, %           | 13                | 9                     | .5      |
| Tacrolimus, %                | 85                | 100                   | .01     |
| Mycophenolate mofetil, %     | 53                | 78                    | .004    |
| mTOR inhibitors, %           | 40                | 19                    | .006    |
| Bolus steroids 1 y before, % | 37                | 42                    | .7      |
| Thymoglobulin 1 y before, %  | 20                | 34                    | .1      |

mTOR, mammalian target of rapamycin.

Table 2. Multivariate Logistic Regression Analyses of Factors Affecting Vaccine Response in Kidney Transplant Recipients

| Variable              | OR  | 95% CI          | P Value |
|-----------------------|-----|-----------------|---------|
| Model 1               |     |                 |         |
| Recipient age         | 1.029| 1.001-1.05      | .04     |
| Diabetes mellitus     | 2.8  | 1.2-6.9         | .02     |
| Mycophenolate mofetil | 2.6  | 1.08-6.8        | .03     |
| Proteinuria           | 1.0  | 1.000-1.001     | .2      |
| Model 2               |     |                 |         |
| Recipient age         | 1.028| 1.001-1.005     | .04     |
| Diabetes mellitus     | 2.9  | 1.2-7.9         | .01     |
| mTOR inhibitors       | 0.3  | 0.1-0.9         | .04     |
| Proteinuria           | 1.0  | 1.0-1.001       | .3      |

mTOR, mammalian target of rapamycin; OR, odds ratio.
DISCUSSION

KT recipients have a greater risk of severe COVID-19 because of the immunosuppression needed to prevent graft rejection. Accordingly, vaccination is a crucial measure to prevent infection, with its resulting associated morbidity and mortality. This is why Western countries have given priority to these patients in vaccination campaigns against COVID-19. However, in immunocompromised persons, such as KT recipients, the humoral immune response seems to be reduced [4]. Among the factors shown to be associated with a poor response to the vaccine are patient age, immunosuppressive treatment with MMF, and high doses of corticoids [3].

Our study found that only 40% of the patients developed antibodies after receiving 2 doses of the COVID-19 vaccine, and of those who failed to respond after the second dose, just 30% responded after the third dose—data that coincide with those reported elsewhere [5]. Among the factors associated with a lack of humoral response were greater patient age, the presence of diabetes mellitus, and immunosuppression with MMF, which are factors also already described [3], whereas those patients who received mTORi had a better response [6].

DISCLOSURE

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

ACKNOWLEDGMENTS

We thank the kidney transplantation team of Hospital Regional Universitario de Málaga for their collaboration. We also thank Ian Johnstone for linguistic assistance in the preparation of the text.

REFERENCES

[1] Caillard S, Chavarot N, Francois H, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant 2021;21:1295–303.
[2] Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.
[3] Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021;21:2719–26.
[4] Marinaki S, Adamopoulos S, Degiannis D, Rousos S, Pavlopoulos ID, Hatrakis A, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant 2021;21:2913–5.
[5] Werbel W, Boyarsky B, Ou M, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med 2021;174:1330–2.
[6] Giuseppe N, Infante B, Troise D, et al. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant 2022;22:1475–82.